Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MannKindSTU:NNFN +6.66%71 Buyback Yield % is -0.01 as of Aug. 20, 2026. GuruFocus rates STU:NNFN with a GF Score™ of 71/100 and a GF Value™ of €6.46 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 710 Biotechnology companies, MannKind ranks better than 88.03% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for MannKind's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:NNFN vs ABSI, ORIC, ARDX: Buyback Yield % Comparison
For the Biotechnology subindustry, MannKind's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MannKind Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MannKind's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where MannKind's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MannKind (STU:NNFN) has a Buyback Yield % of -0.01 as of Aug. 20, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MannKind and its competitors. According to the industry distribution chart, MannKind ranks #85 out of 710 companies in the Biotechnology industry, placing it in the top 12%.
Is MannKind's Buyback Yield % too high?
MannKind's current Buyback Yield % is -0.01. Based on the distribution chart, MannKind ranks #85 out of 710 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MannKind has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MannKind's Buyback Yield % compare to ABSI and ORIC?
According to the Biotechnology industry distribution chart, MannKind ranks #85 out of 710 companies for Buyback Yield %. This places MannKind in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MannKind and its competitors. MannKind's current Buyback Yield % is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MannKind stock overvalued right now?
Based on GuruFocus' analysis, MannKind (STU:NNFN) is currently considered Possible Value Trap. The stock's GF Value™ is €6.46, compared to a current price of €3.73 — trading 42.2% below its estimated fair value. The current Buyback Yield % is -0.01. MannKind's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For MannKind (STU:NNFN), the current Buyback Yield % is -0.01 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MannKind (STU:NNFN) Overvalued in 2026?
Based on GuruFocus' analysis, MannKind stock appears to be undervalued.
The current stock price of €3.73 is trading 42.2% below its estimated GF Value™ of €6.46.
GuruFocus considers MannKind to be Possible Value Trap.
Key valuation signals for STU:NNFN:
Buyback Yield %: -0.01
GF Value™: €6.46 vs. price of €3.73 (42.2% below fair value)
No single metric tells the full story. See the STU:NNFN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
71GF Score
Get the complete analysis for STU:NNFN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:NNFN has been successfully added to your 
